Claims for Patent: 8,697,747

Summary for Patent: 8,697,747

Title:	Enhancing coagulation or reducing fibrinolysis
Abstract:	Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).
Inventor(s):	Nielsen; Vance G. (Moorestown, NJ), George; James F. (Birmingham, AL), Kirklin; James K. (Birmingham, AL)
Assignee:	THe UAB Research Foundation (Birmingham, AL)
Application Number:	13/254,287
Patent Claims:	1. A method for enhancing coagulation or reducing fibrinolysis in a subject, comprising: a) selecting a subject in need of enhanced coagulation or reduced fibrinolysis; and b) administering to the subject a carbon monoxide releasing molecule (CORM). 2. The method of claim 1, wherein the CORM is a tricarbonyldichlororuthenium (II) dimer. 3. The method of claim 1, wherein the CORM is selected from the group consisting of tricarbonylchloro(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. 4. The method of claim 1, wherein a single dose of the CORM is administered to the subject. 5. The method of claim 4, wherein the dose comprises 25 .mu.M to 200 .mu.M of the CORM. 6. The method of claim 1, wherein the CORM is administered at or near a site of bleeding. 7. The method of claim 1, wherein the CORM is administered topically, by local injection, intravenously, or intramuscularly. 8. The method of claim 1, wherein the CORM is formulated for administration by an aerosol spray, an ointment, a bandage, a surgical dressing, a wound packing, a swab, a liquid, a paste, a cream, a lotion, a foam, a gel, an emulsion, a powder, dental floss, a dental instrument, or a needle. 9. The method of claim 1, wherein the CORM is co-administered with a hemostatic agent, a coagulant, an anti-fibrinolytic medication, a blood coagulation factor, fibrin, thrombin, recombinant activated factor VII, prothrombin complex concentrate, FEIBA, or a therapeutic agent selected from the group consisting of an antibiotic, an anesthetic, an analgesic, an antihistamine, an antimicrobial, an antifungal, an antiviral, and an anti-inflammatory agent. 10. The method of claim 9, wherein the blood coagulation factor is factor VIII, factor IX, factor XIII, or von Willebrand's factor. 11. The method of claim 1, wherein the subject has a disease or condition associated with bleeding. 12. The method of claim 11, wherein the disease or condition associated with bleeding is hemophilia, thrombocytopenia, von Willebrand disease, hereditary hemorrhagic telangiectasia, disseminated intravascular coagulation, or an open wound. 13. The method of claim 12, wherein the open wound is caused by trauma or injury or is due to a surgical procedure. 14. The method of claim 1, wherein the subject is undergoing surgery or hemodilution. 15. The method of claim 1, wherein the subject is in need of increased blood clot formation. 16. The method of claim 15, wherein the subject is being treated with an anticoagulant, an antiplatelet medication, an anti-thrombin, or a fibrinolytic medication.

Details for Patent 8,697,747

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	12/21/1979		2029-03-05
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	07/31/2000		2029-03-05
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	08/11/2005		2029-03-05